Johns Hopkins Medicine Office of Continuing Medical Education
Skip Navigation.
How ToAbout CMECME CalendarOnline/EnduringProgramsResources & DownloadsContact & Travel InformationBlog
CME Online
Forgot your password?

Not Registered yet?

Create a new account.

80027953: 16th Update in Hematologic Malignancies

April 27, 2012
  • Download Brochure
  • Send to Colleague
  • Back to List
U16th Annual Update in Hematologic Malignancies Brochure Cover Image

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDIT
American Nurses Credentialing Center
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 6.75 hours of Category 1 credit for completing this program.


Description

Medicine is rapidly changing and new therapeutic options are emerging in all areas including oncology and the hematologic malignancies. New diagnostic and treatment strategies are emerging at a rapid pace and physicians, nurses and allied health professionals need to have an in-depth knowledge of the latest clinical and research advancements in order to provide the best care to their patients. This activity will provide an up-to-date assessment of current and emerging strategies for treating hematologic malignancies - from biologically-based approaches to novel therapeutics and bone marrow transplantation as well as providing state-of-the-art data on novel biomarkers, diagnostic tools and the application of these in the diagnosis and management of hematologic malignancies.

Objectives

After attending this activity, the participant will demonstrate the ability to:
  • Discuss the role of bone marrow transplantation in the treatment of a range of hematologic malignancies
  • Develop and implement a comprehensive treatment strategy for patients with myeloproliferative disorders
  • Describe state-of-the-art treatment strategies for adolescents and young adults with Acute Lymphoblastic Leukemia (ALL)
  • Discuss the emerging area of personalized medicine and its application to hematologic malignancies
  • Discuss immunotherapeutic strategies in the treatment of hematologic malignancies
  • Formulate appropriate treatment strategies for the management of infectious complications in patients with hematologic malignancies
  • Discuss the approach to treatment of Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) in 2012

REGISTRATION CUT-OFF DATE: April 21, 2012

Talks

April 27, 2012  8:30 AM to 9:15 AM

The First Hayden Grant Braine, MD Lecture: Multiple Myeloma - Therapy in 2012: Towards a Personalized Approach

Orlowski, Robert
Identify current standards of care for multiple myeloma therapy. Discuss challenges for developing personalized therapeutic approaches.
April 27, 2012  9:15 AM to 9:45 AM

Personalized Medicine

Nelson, William
Describe how genomics and epigenomics assays are increasingly impacting on daily medical oncology practice State why repeated genome and epigenome assessments may be needed to direct therapy in the setting of resistance to initial treatment Discuss how specific genome and epigenome defects are being targeted with new therapeutic agents
April 27, 2012  9:45 AM to 10:15 AM

Personalized Therapy for AML: Perspective from the Clinic

Gojo, Ivana
Describe how cytogenetic and molecular abnormalities are currently impacting the decisions on induction and post-remission therapeutic strategies. Discuss how specific molecular abnormalities are being targeted with novel therapeutic agents.
April 27, 2012  10:30 AM to 11:00 AM

CLL: Personalized Approach to Treatment

Gladstone, Douglas
Risk stratify CLL patients who harbor both low and high risk factors
April 27, 2012  11:00 AM to 11:30 AM

JAK2V617F Disease: A Personalized Approach

Moliterno, Alison
Define the role of acquired somatic mutations in the Myeloproliferative Neoplasms (MPN) Discuss the clinical and molecular features of JAK2V617F-positive MPN Review the molecular lesions associated with disease progression in the JAK2V617F-positive MPN and their relationship to targeted therapies
April 27, 2012  11:30 AM to 12:00 PM

ALL in Adolescents and Young Adults

Brown, Patrick
Describe the rationale for treating ALL in adolescents and young adults with "pediatric inspired" treatment regimens
April 27, 2012  1:00 PM to 1:30 PM

Case Discussions- Moderator

Jones, Richard
April 27, 2012  1:00 PM to 1:30 PM

Case Discussions- Panelist

Appelbaum, Frederick
April 27, 2012  1:00 PM to 1:30 PM

Case Discussions- Panelist

Gladstone, Douglas
April 27, 2012  1:00 PM to 1:30 PM

Case Discussions- Panelist

Gojo, Ivana
To review approaches to AML treatment based on patient and disease characteristics
April 27, 2012  1:30 PM to 2:30 PM

The 14th George Santos, MD Lecture: The Grand Challenges of Allogeneic Hematopoietic Cell Transplantation

Appelbaum, Frederick
Discuss the current research directions in hematopoeitic cell transplantation.
April 27, 2012  2:30 PM to 3:00 PM

Bone Marrow Transplantation for Non-malignant Diseases

Brodsky, Robert
Discuss indications for transplanting non-malignant diseases Discuss use of high dose cyclophosphamide to mitigate graft versus host disease
April 27, 2012  3:15 PM to 4:00 PM

Treating CLL with Genetically Engineered T-Cells

Porter, David
Describe the role of cellular therapy for CLL and other CD19+ malignancies
April 27, 2012  4:00 PM to 4:45 PM

Infectious Complications: Prevention and Treatment

Marr, Kieren
To review most recent data on prevention and treatment of select infections in patients with hematologic malignancies.

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.

Event Information
Johns Hopkins Hospital, Sidney Kimmel Cancer Center Bldg II
1550 Orleans St, CRB II
Baltimore, MD
Directions

Target Audience(s)

This activity is intended for medical oncologists, nurse practitioners, physician assistants, and other allied health professionals.

Course Director

Carol Huff

Contact Info

General Info: 410.502.9634

Mailing Address:
Johns Hopkins University School
of Medicine
Thomas B. Turner Building
720 Rutland Avenue, Room 20
Baltimore, Maryland 21205-2195

Email Us

© 2012 Johns Hopkins University
School of Medicine | Office of Continuing Medical Education
Home | Privacy Policy | Sitemap
Managed Hosting by PEER 1
HTML to PDF conversion by ABCpdf.NET